Inoviq Ltd
IIQ
Company Profile
Business description
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
Contact
23 Normanby Road
Notting Hill
MelbourneVIC3168
AUST: +61 395487586
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,999.00 | 16.40 | -0.18% |
CAC 40 | 7,861.96 | 4.60 | 0.06% |
DAX 40 | 24,262.22 | 44.85 | 0.19% |
Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
FTSE 100 | 9,136.94 | 0.62 | 0.01% |
HKSE | 24,796.46 | 380.47 | -1.51% |
NASDAQ | 21,129.67 | 31.38 | 0.15% |
Nikkei 225 | 41,100.73 | 446.03 | 1.10% |
NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
S&P 500 | 6,362.90 | 7.96 | -0.12% |
S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
SSE Composite Index | 3,572.24 | 43.47 | -1.20% |